Decreased expression and epigenetic silencing of RELN has previously been associated with advanced stage and poor prognosis in several cancers [43–47] and recent work has shown that loss of RAS signaling by disrupting interactions with PI3K increases extracellular RELN levels, resulting in decreased tumor aggressiveness via activation of cell adhesion pathways [48]. The gene discussed is RELN; the disease is cancer.